Dataset Information

Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data.

ABSTRACT:

Background and aims

The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.

Methods

We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.

Results

All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.

Conclusion

In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.

SUBMITTER: Attauabi M

PROVIDER: S-EPMC8689957 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundReal-world data on long-term outcomes of vedolizumab (VDZ) are scarce.ObjectiveTo assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD).DesignA nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Effectiveness And Healthcare resource utilization in patients with IBD (SVEAH).MethodsAfter re-consent, data of patients with Crohn's disease (CD) (n = 68) and ulcerative colitis (UC) (n = 46) treated with VDZ were prospectively recorded using an electronic case report form integrated with the Swedish IBD Register (SWIBREG). The primary outcome was clinical remission (defined as Harvey-Bradshaw Index ⩽4 in CD and partial Mayo score ⩽2 in UC) at 104 and 156 weeks in patients with a response and/or remission 12 weeks after starting VDZ. Secondary outcomes included health-related quality of life (HRQoL) and biochemical outcomes.ResultsVDZ continuation rates were high at weeks 104 and 156, 88% and 84%, respectively, for CD and 87% and 78%, respectively, for UC. Of the 53 CD patients with a response/remission at 12 weeks, 40 (75%) patients were in remission at 104 weeks and 42 (79%) patients at 156 weeks. For UC, these numbers were 25/31 (81%) and 22/31 (71%), respectively. Improvements were seen in the Short Health Scale (p < 0.01 for each dimension; CD, n = 51; UC, n = 33) and the EuroQol 5-Dimensions, 5-levels index value (p < 0.01; CD, n = 39; UC, n = 30). Median plasma-C-reactive protein concentrations (mg/L) decreased from 5 at baseline to 4 in CD (p = 0.01, n = 53) and from 5 to 4 in UC (p = 0.03, n = 34) at 156 weeks. Correspondingly, median faecal-calprotectin (µg/g) decreased from 641 to 114 in CD patients (p < 0.01, n = 26) and from 387 to 37 in UC patients (p = 0.02, n = 17).ConclusionVDZ demonstrated high continuation rates and was associated with improvements in clinical outcomes, HRQoL measures and inflammatory markers at 2 and 3 years after treatment initiation in this prospective national SVEAH extension study.RegistrationENCePP registration number: EUPAS22735.